Floatz logo

Eloralintide

Osteoarthritis

Eli Lilly and Companyprotein_peptidePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

14 Active assets in the Osteoarthritis cohort.

Asset / SponsorPhaseRating
Naltrexone
Brigham and Women's Hospital
Phase 4BBB
Buprenorphine
Mundipharma Pte Ltd.
Phase 4BBB
Oxycodone
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 4BBB
FENTANYL
Janssen Pharmaceutica
Phase 4BBB
Liraglutide
Henrik Gudbergsen
Phase 4BBB

View all 48 →

Same molecule, other indications

Eloralintide is also rated in:

obesity disorderDormant
B
Indicative ·
60 / 100
View asset →
obstructive sleep apnea syndromeDormant
B
Indicative ·
60 / 100
View asset →
obesity disorderDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →